Stocks and Investing
Stocks and Investing
Wed, May 11, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Do Kim Maintained (ABCL) at Buy with Decreased Target to $21 on, May 11th, 2022
Do Kim of Piper Sandler, Maintained "AbCellera Biologics Inc." (ABCL) at Buy with Decreased Target from $28 to $21 on, May 11th, 2022.
Do has made no other calls on ABCL in the last 4 months.
There is 1 other peer that has a rating on ABCL. Out of the 1 peers that are also analyzing ABCL, 0 agree with Do's Rating of Hold.
This is the rating of the analyst that currently disagrees with Do
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Increased Target to $40 on, Friday, February 25th, 2022
Contributing Sources